Huberman LabNicotine’s Effects on the Brain & Body & How to Quit Smoking or Vaping
CHAPTERS
- 0:00 – 9:50
Introduction, Scope, and Separating Nicotine from Smoking
Huberman introduces the episode’s focus on nicotine as a molecule distinct from its delivery methods like smoking and vaping. He previews a nuanced treatment of nicotine’s benefits, harms, and its role in addiction, especially in the context of rising vaping among youth.
- •Nicotine is one of the most widely consumed psychoactive substances on Earth, mostly via tobacco.
- •Delivery routes include smoking, vaping, dip, snuff, patches, gums, pills, and infused products.
- •The episode will separate the pharmacology of nicotine from the toxicities of delivery devices.
- •Smoking and vaping are strongly detrimental to health, but certain controlled nicotine uses may have narrow, context-specific benefits.
- •Vaping in young people is rising and can create addiction not only to nicotine but to associated behaviors.
- 9:50 – 25:20
Focus Toolkit Recap and Arrow Model of Attention
Before diving into nicotine, Huberman revisits core tools and neurochemistry of focus—laying groundwork for understanding why nicotine powerfully enhances concentration and drive. He explains a simple daily meditation and the ‘arrow model’ of focus involving acetylcholine, epinephrine, and dopamine.
- •A 13‑minute daily focused-attention meditation (forehead/behind-the-eyes focus) significantly improves focus capacity per Wendy Suzuki’s lab.
- •Effectiveness stems from repeatedly refocusing attention when it drifts, strengthening attentional control circuits.
- •Arrow model: acetylcholine sets direction (arrowhead), epinephrine provides energy (shaft), dopamine supplies motivation (propeller).
- •Alpha‑GPC (300 mg pre‑work) can transiently boost acetylcholine and epinephrine for focused tasks, but is not required.
- •Potential TMAO increase from Alpha‑GPC can be offset with garlic; behavioral tools are prioritized over supplements or prescription stimulants.
- 25:20 – 41:10
Sponsor Messages and Nootropics Framing
Huberman provides sponsor reads (Thesis, InsideTracker, ROKA) and contextualizes his skepticism about the term “nootropics”. He emphasizes there is no single “smart drug,” only interventions that target specific brain states like focus, creativity, or task switching.
- •Thesis offers customized nootropic blends tailored to desired states (clarity, energy).
- •Huberman rejects the idea of universal ‘smart drugs’; different circuits control focus, creativity, etc.
- •InsideTracker uses blood and DNA data to guide personalized nutrition and lifestyle changes.
- •ROKA eyeglasses/sunglasses are designed for performance and visual clarity.
- 41:10 – 50:50
Why the Brain Has Nicotinic Receptors and a Nicotine Anecdote
Huberman frames nicotine within evolutionary biology, stressing that nicotinic receptors exist for acetylcholine signaling, not because of tobacco. He shares a story of a Nobel Prize–winning neuroscientist who quit smoking but still chews nicotine gum for perceived cognitive protection and focus.
- •Nicotinic acetylcholine receptors evolved for endogenous acetylcholine; tobacco/nicotine later hijacked them.
- •Nicotine may have neuroprotective roles in specific contexts (e.g., cognitive decline), but smoking remains highly harmful.
- •A famous neuroscientist reports using nicotine gum to maintain cognition after quitting smoking despite cardiovascular damage from prior cigarette use.
- •Nicotine’s net effects are dose- and pattern-dependent; high or chronic doses can impair cognition.
- 50:50 – 59:40
What Nicotine Is, Where It’s Found, and Insect Defense
The discussion shifts to nicotine’s origin as a plant alkaloid found in tobacco and nightshades, likely evolved as an insecticide. Huberman explains why nicotine is lethal or sterilizing to insects but has different, primarily neuromodulatory effects in humans.
- •Nicotine is present in tobacco, tomatoes, eggplants, sweet peppers, and potatoes (much lower levels in food plants).
- •As a plant alkaloid, nicotine likely evolved to deter insects by disrupting their nervous systems and reproduction.
- •In humans, different receptor expression and distribution lead to psychoactive rather than sterilizing/lethal effects.
- •Nicotine can affect human reproductive function indirectly (e.g., via blood flow and endothelial effects) but does not sterilize humans.
- 59:40 – 1:07:00
Routes of Absorption, Blood–Brain Barrier, and Nicotinic Receptors
Huberman explains how nicotine is absorbed through lungs or mucosal membranes and rapidly reaches the bloodstream and brain. He introduces nicotinic versus muscarinic acetylcholine receptors and identifies the key receptor subtype responsible for many central effects.
- •Nicotine enters through inhalation (smoking/vaping) or mucosal contact (mouth, nose) and reaches blood in 2–15 minutes.
- •It crosses the blood–brain barrier due to its fat solubility (lipophilicity).
- •Nicotinic acetylcholine receptors are a family of receptor subtypes distinct from muscarinic receptors.
- •The alpha4beta2 nicotinic receptor is critical for central effects, including appetite suppression and reward.
- 1:07:00 – 1:20:20
Nicotine’s Effects on Reward, Focus, and Arousal: Dopamine, Acetylcholine, Norepinephrine
Here Huberman details nicotine’s three major neurochemical actions in the brain: potentiating dopamine reward, sharpening focus via acetylcholine, and elevating arousal via norepinephrine. He links these to nicotine’s subjective effects and its capacity to shape motivation and mood.
- •Dopamine: nicotine stimulates dopamine release in nucleus accumbens and VTA outputs, enhancing reinforcement and motivation.
- •Nicotine also reduces GABAergic braking in reward circuits, amplifying dopamine surges (accelerator pressed, brake released).
- •Acetylcholine: nicotine increases acetylcholine from nucleus basalis, spotlighting active circuits and enhancing attention on tasks.
- •Norepinephrine/epinephrine: release from locus coeruleus increases alertness and energy; Huberman lumps NE/epinephrine/adrenaline functionally.
- •Combined dopamine–ACh–NE activation creates a potent state of elevated mood, focus, and wakefulness lasting ~30–45 minutes after a dose.
- •Short half-life (1–2 hours) drives chain smoking or frequent vaping to maintain desired state.
- 1:20:20 – 1:29:40
Appetite Suppression and Metabolism via Hypothalamic POMC Neurons
Huberman describes how nicotine reduces appetite and modestly increases metabolism through specific hypothalamic neurons. He ties this to concerns about weight gain after quitting and sociocultural drivers of nicotine use.
- •POMC neurons in the hypothalamus regulate satiety and appetite.
- •Nicotine binds alpha4beta2 receptors on POMC neurons, increasing their activity and suppressing hunger.
- •Pathways influence subjective fullness, blood sugar, and even motor drive to chew, reducing oral intake behaviorally.
- •Nicotine transiently elevates metabolism by ~2–5%, contributing modestly to weight control.
- •Fear of post‑cessation weight gain—especially among young women—is a major barrier to quitting.
- 1:29:40 – 1:42:40
Peripheral Effects: Cardiovascular Activation, Vascular Constriction, and Muscle Relaxation
The conversation moves from brain to body, covering nicotine’s acute systemic effects on heart, blood pressure, vascular tone, and skeletal muscle. Huberman explains why these effects make nicotine poor for physical performance yet attractive for mental work.
- •Nicotine increases heart rate, blood pressure, cardiac contractility, and sympathetic nervous system tone.
- •It triggers adrenal epinephrine release, preparing the body for action.
- •Simultaneously, it constricts blood vessels, which can acutely reduce penile girth and compromise genital blood flow.
- •Chronic use (especially via smoke/vape) damages endothelial cells, undermining blood delivery to all organs.
- •Paradoxically, nicotine can relax skeletal muscles via upstream circuit effects, creating a state of mentally alert but physically relaxed—ideal for cognitive work, poor for athletic performance.
- •Nicotine is therefore a bad pre‑workout choice, especially when delivered by smoke/vape that directly impairs lung function.
- 1:42:40 – 1:47:30
Developmental Risk: Why Youth Should Avoid Nicotine
Huberman cautions strongly against nicotine use in adolescents and young adults, emphasizing that the still-developing brain is particularly vulnerable to addiction and long-term dopaminergic changes. He delineates age thresholds and circumstances where nicotine might be considered.
- •Brain development and high neuroplasticity extend through puberty and into the mid‑20s.
- •Nicotine use in youth embeds dependence on exogenous modulation of focus, mood, and motivation circuits.
- •For those under ~25, using nicotine as a cognitive enhancer is strongly discouraged absent a clinical indication.
- •Even in adults, frequent nicotine use risks dependence; occasional, strategic use (if any) should not involve smoking, vaping, dip, or snuff.
- •Behavioral and nutritional focus tools are preferred first‑line strategies at all ages.
- 1:47:30 – 1:58:10
Global Health Toll of Smoking, Vaping, Dip, and Snuff
Returning to delivery systems, Huberman outlines the vast health damage from cigarettes, vapes, dip, and snuff. He reviews carcinogens, vascular damage, and organ-level consequences, then quantifies life years lost and the global prevalence of tobacco use.
- •Cigarettes contain 4,000–7,000 toxins, including major carcinogens: tar, ammonia, formaldehyde, carbon monoxide/CO₂.
- •Carbon monoxide/CO₂ binds hemoglobin and impairs oxygen delivery, compromising organ function.
- •All tobacco delivery methods severely damage endothelial cells, impairing vasculature throughout the body.
- •Estimated: each pack of cigarettes per day shortens life expectancy by ~14 years.
- •Dip and snuff increase oral and nasal cancer risk dramatically (dip ~50‑fold oral cancer increase).
- •Smoking and vaping drive increased risk of stroke, heart attack, peripheral vascular disease, cognitive decline, sexual dysfunction, and hormonal disruption.
- •Over one billion people smoke, and hundreds of millions vape, with many being dual users; total tobacco users globally reach into the billions.
- 1:58:10 – 2:02:40
Cognitive Decline Despite Nicotine’s Acute Cognitive Benefits
Huberman reconciles nicotine’s short-term cognitive enhancement with long-term cognitive harm from smoking and vaping. He attributes impairments to chronic vascular damage and impaired nutrient delivery to the brain.
- •The brain is the most metabolically demanding organ and highly dependent on intact vasculature.
- •Chronic endothelial disruption reduces nutrient and oxygen delivery, accumulating debris and impairing neural function.
- •Smokers and vapers experience declines in short-term and working memory, as well as planning and prospective memory.
- •Thus, while nicotine acutely boosts attention and working memory, chronic delivery via toxic routes causes net cognitive decline over time.
- 2:02:40 – 2:14:30
Why Quitting Is So Hard: Addiction, Withdrawal, and Craving
Huberman explains the addiction cycle in terms of dopamine dynamics and mesolimbic reward circuitry. He defines addiction as a narrowing of pleasurable activities and describes nicotine withdrawal’s onset and symptoms.
- •More than 70% of cigarette smokers report wanting to quit but feel unable.
- •Addiction is framed as a progressive narrowing of the things that bring pleasure.
- •Craving is a biologically measurable state: dopamine dropping below baseline after repeated peaks.
- •Withdrawal can start ~4 hours after last nicotine use and includes agitation, nausea, irritability, and strong cravings.
- •Vaping’s rapid delivery and controllable dosing intensify this dynamic, making it even harder to quit than cigarettes for many.
- 2:14:30 – 2:26:00
Vaping vs. Smoking: Cocaine Analogy and Dopamine Kinetics
He draws a detailed analogy between cocaine delivery routes and nicotine delivery, especially vaping, to illustrate why speed of brain entry amplifies addiction. Vaping’s pharmacokinetics are likened to crack cocaine in terms of rapid dopamine ramping.
- •Cocaine routes: snorting (like snuff), ingestion, injection, crack smoking (rapid vaporized delivery).
- •Vaping nicotine uses low-heat aerosolization, delivering nicotine faster than cigarettes.
- •Addiction severity correlates not only with dopamine peak size but also slope (speed of rise).
- •Vaping produces steeper, faster dopamine increases than smoking, increasing reinforcing power.
- •Young vapers often dose repeatedly throughout the day, especially in school settings, deeply conditioning dopamine circuits.
- •This pattern is strongly associated with increased depression when use decreases or stops.
- 2:26:00 – 2:31:00
Cold Turkey Outcomes and the Need for Better Quitting Tools
Huberman presents sobering statistics about unaided quit attempts, then transitions to evidence-based interventions. He stresses that despite low base success rates, there are robust methods that substantially improve the odds.
- •Only ~5% of smokers who quit cold turkey (no support) succeed long-term.
- •Of those 5%, about 65% relapse within a year.
- •Despite health, financial, and social costs, neurochemical reinforcement keeps people using nicotine.
- •There is good evidence for both behavioral (hypnosis) and pharmacologic approaches that improve quit rates well above cold turkey.
- 2:31:00 – 2:38:00
Clinical Hypnosis for Smoking and Vaping Cessation
Huberman highlights Dr. David Spiegel’s work on clinical hypnosis as a powerful, low-risk intervention for quitting. He distinguishes clinical from stage hypnosis and points to the Reveri app as an accessible tool.
- •Clinical hypnosis is patient-directed rewiring of brain circuits for specific behavioral/emotional goals, not stage entertainment.
- •A single standardized hypnosis session for smoking cessation achieved ~23% complete cessation in research, far above 5% baseline.
- •Reveri app (reveri.com) now delivers Spiegel’s protocols, including scripts aimed at smoking/vaping/dip/snuff cessation.
- •Hypnosis likely works by remapping default-mode and interoceptive networks, changing how internal urges and cues are processed.
- •Given minimal risk and no pharmacologic side effects, hypnosis is a high-leverage option to try when quitting.
- 2:38:00 – 2:48:00
Pharmacologic Aids: Bupropion and Other Medications
The episode reviews pharmacologic approaches to smoking cessation, centering on bupropion (Wellbutrin). Huberman describes its mechanism, dosing, risks, and efficacy compared to hypnosis and cold turkey.
- •Key review: “Pharmacologic Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice” (2020).
- •Bupropion (Wellbutrin) is a dopamine/norepinephrine modulator used as both an antidepressant and smoking-cessation aid.
- •Typical regimen: ~300 mg/day (often 150 mg twice daily), but individualized by a physician.
- •Risks include increased seizure susceptibility and caution in liver/renal disease or with certain sedatives/benzodiazepines.
- •Bupropion can raise quit rates to roughly 20%, similar to hypnosis.
- •Other agents (e.g., SSRIs) are less central in this episode but are part of broader cessation pharmacology.
- 2:48:00 – 2:57:00
Nicotine Replacement Therapy: Patches, Gum, Sprays, and Kinetic Strategy
Huberman explains how nicotine itself can be used—via safer routes—to quit smoking and vaping. He emphasizes that mixing and timing different delivery forms to vary dopamine kinetics improves success.
- •Nicotine replacement aims to decouple nicotine intake from harmful delivery devices (cigarettes/vapes/dip/snuff).
- •Tools include transdermal patches, gums, lozenges, and nasal sprays.
- •Best results arise from combining modalities over time: e.g., a week on patches, then a week on gum, then sprays, etc.
- •Patches provide relatively steady-state blood nicotine and dopamine levels over the day.
- •Gum/sprays introduce faster spikes; rotating them keeps the reward system from locking into one pattern.
- •Varying dopamine amplitude and timing leverages the power of intermittent, less predictable reward to disrupt rigid addiction patterns.
- 2:57:00 – 3:11:40
Dopamine Homeostasis, Baseline Shifts, and the Critical First Week
This segment offers a mechanistic model of withdrawal using dopamine homeostasis and daily rhythms of arousal. Huberman explains why specific times of day are hardest after quitting and how to strategically support dopamine during that week.
- •Chronic nicotine use lowers baseline arousal/dopamine to offset frequent peaks (homeostatic adaptation).
- •When nicotine is removed, baseline remains low, but spikes vanish—making ex‑‘cigarette times’ feel markedly worse than pre‑use life.
- •This leads to acute dysphoria, especially at habitual use times (e.g., morning, afternoon breaks).
- •About 75% of people relapse within the first week; that window is the highest-risk interval.
- •Supporting dopamine via healthy behaviors—exercise, deliberate cold exposure, positive social interaction, hypnosis—during those moments is critical.
- •Understanding the biology can help individuals anticipate and plan for these dips instead of being blindsided.
- 3:11:40 – 3:18:00
Long-Term Maintenance and Alcohol as a Relapse Trigger
Huberman addresses the importance of ongoing reinforcement of non-nicotine circuits and flags alcohol as a key relapse risk. He recommends periodic hypnosis sessions even after successful cessation.
- •Even after initial cessation, periodic maintenance (e.g., weekly or monthly hypnosis) helps ‘tighten’ the neural circuits supporting abstinence.
- •Alcohol consumption is strongly associated with relapse in former smokers/vapers due to cross‑sensitization and disinhibition.
- •Avoiding or minimizing alcohol during and after quitting significantly lowers relapse risk.
- •Reinforcing alternative reward pathways—exercise, meaningful work, relationships—helps broaden the range of things that bring pleasure, reversing addiction’s narrowing.
- 3:18:00 – 3:27:20
Recap: Nicotine’s Power, its Pitfalls, and Safer Strategies
In closing, Huberman reiterates that nicotine is an exceptionally potent neuromodulator that can enhance cognition but carries major addiction and health risks via common delivery methods. He urges behavioral focus tools first and frames occasional adult nicotine use, if any, as a last resort and never via smoke or vape.
- •Nicotine robustly activates dopamine, acetylcholine, and norepinephrine circuits, explaining its strong subjective benefits.
- •Smoking, vaping, dip, and snuff are catastrophic for vascular, brain, and overall health; nicotine is not the carcinogen but is tightly bound to carcinogenic delivery methods.
- •Occasional non-combustion nicotine use may have niche cognitive applications in adults, but dependence risk is real.
- •Behavioral tools (meditation, structured focus, sleep optimization), nutrition, and select supplements (e.g., Alpha‑GPC) are safer for focus and performance.
- •With the right combination of understanding, hypnosis, pharmacology, and dopamine-supportive behaviors, most people can quit nicotine-delivery addictions.
- 3:27:20
Outro, Sponsors, and Newsletter
Huberman wraps up with standard calls to action—subscribing, supporting sponsors, and using his free newsletter. He reinforces his mission to provide zero‑cost science and tools to the public.
- •Encourages subscribing on YouTube, Apple, Spotify, and leaving reviews.
- •Mentions sponsors like Momentous and Athletic Greens (AG1) for supplements.
- •Promotes the free Huberman Lab Newsletter with science-based toolkits.
- •Directs listeners to social media channels for additional, often distinct content.
- •Reiterates gratitude and the aim of making science-based tools widely accessible.
